Paige.AI, the startup focused on clinical diagnosis and treatment in pathology and oncology through the use of artificial intelligence (AI), announced that Dr. Leo Grady has joined the company as Chief Executive Officer and a member of its Board of Directors.
Grady has more than 15 years of experience in prototyping, developing, and bringing to market some of the industry’s most advanced machine learning, computer vision, and medical imaging technologies and products. Prior to joining Paige.AI, Grady was Senior Vice President of Engineering for HeartFlow, a leading medical technology company recently valued at more than $1.5 billion, that leverages deep learning to transform the way cardiac disease is diagnosed and treated.
Paige.AI was launched in 2018 based on technology developed by its Co-Founder and Chief Scientific Officer, Dr. Thomas Fuchs, and a license agreement with Memorial Sloan Kettering Cancer Center (MSK). Paige.AI is well on its way to digitizing five million pathology slides from MSK’s enormous archive, giving the company an unparalleled database on which to build its AI. In its first year, Paige.AI has hired an outstanding group of AI scientists and software engineers who are working to create fundamental advances in computational pathology, initially focused on developing a full suite of modules and products to serve the needs of diagnostic pathologists around the world.
“The Board is thrilled to welcome Leo to the Paige.AI team as our new CEO,” said Jim Breyer, CEO of Breyer Capital, a premier global venture capital firm and a lead Paige.AI investor. “Leo is an accomplished healthcare technology executive who has successfully led the development and commercialization of transformative technologies rooted in medical imaging and machine learning. With those strong credentials in both the business and scientific arenas, Leo is highly regarded and ideally positioned to help build on Paige.AI’s uniquely compelling foundation of world-class AI, data at scale, and excellent clinical expertise.”
“Leo’s demonstrated business and leadership acumen at cutting-edge healthcare technology organizations, grounded in his capabilities as a scientist and engineer, make him a great cultural fit and the ideal CEO to help us take Paige.AI to the next level,” said Fuchs. “The entire team looks forward to working with him in advancing our mission of developing AI and machine learning to help pathologists and physicians deliver better, more customized care for cancer patients around the world.”
“I am deeply honored to have the opportunity to lead and work alongside Paige.AI’s growing team of the industry’s best and brightest minds, and I appreciate the confidence the Board and my new colleagues have placed in me,” said Grady. “Technology innovation in healthcare is taking huge steps forward every day, and Paige.AI is leading the charge by applying AI and machine learning to transform how doctors diagnose and treat cancer. We have a rare opportunity at Paige.AI to provide technology that helps doctors achieve the triple aim of healthcare: improved patient care, improved patient experience and lowered costs. Paige.AI’s mission is one of great purpose and promise and I look forward to working with the team to help realize this company’s enormous potential.”